Loading…
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.8B | $220M | $-1.1B | $-303M | 238.8% | 3.1% | 203.5% |
| 2024 | $2.7B | $-41M | $-363M | $-21M | -61.9% | 5.0% | 778.2% |
| 2023 | $2.6B | $342M | $-41M | $562M | -4.5% | -74.4% | -284.5% |
| 2022 | $10.0B | $368M | $22M | $158M | 2.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 9,955.48 | 2,552.57 | 2,680.11 | 2,762.03 |
| Operating Revenue | - | 9,955.48 | 2,552.57 | 2,680.11 | 2,762.03 |
| Cost Of Revenue | - | 8,129.12 | 1,335.55 | 1,399.73 | 1,472.73 |
| Gross Profit | - | 1,826.35 | 1,217.02 | 1,280.38 | 1,289.30 |
| Operating Expense | - | 1,549.57 | 1,001.66 | 1,082.34 | 1,067.56 |
| Selling General And Administration | - | 1,554.82 | 1,001.66 | 1,082.34 | 1,067.56 |
| Total Expenses | - | 9,678.69 | 2,337.21 | 2,482.08 | 2,540.29 |
| Operating Income | - | 276.78 | 215.36 | 198.04 | 221.74 |
| Total Operating Income As Reported | - | 142.91 | 133.23 | -217.73 | 27.46 |
| EBITDA | - | 368.45 | 342.40 | -41.04 | 219.75 |
| Normalized EBITDA | - | 502.32 | 424.54 | 374.73 | 432.32 |
| EBIT | - | 139.78 | 132.03 | -222.32 | 5.23 |
| Interest Expense | - | 128.89 | 116.77 | 107.57 | 107.18 |
| Net Interest Income | - | -128.89 | -116.77 | -107.57 | -107.18 |
| Other Non Operating Income Expenses | - | -3.13 | -1.20 | -4.59 | -3.94 |
| Other Income Expense | - | -137 | -83.33 | -420.36 | -216.51 |
| Interest Expense Non Operating | - | 128.89 | 116.77 | 107.57 | 107.18 |
| Net Non Operating Interest Income Expense | - | -128.89 | -116.77 | -107.57 | -107.18 |
| Pretax Income | - | 10.89 | 15.26 | -329.88 | -101.95 |
| Tax Provision | - | -11.50 | 6.36 | 20.85 | 0.73 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -28.11 | -17.25 | -87.31 | -44.64 |
| Net Income Continuous Operations | - | 22.39 | 8.90 | -350.74 | -102.68 |
| Net Income From Continuing And Discontinued Operation | - | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income From Continuing Operation Net Minority Interest | - | 22.39 | 8.90 | -350.74 | -102.68 |
| Net Income | - | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income Common Stockholders | - | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income Including Noncontrolling Interests | - | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Normalized Income | - | 128.15 | 73.79 | -22.28 | 65.25 |
| Diluted NI Availto Com Stockholders | - | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Basic Average Shares | - | 74.50 | 75.78 | 76.74 | 76.90 |
| Diluted Average Shares | - | 76.22 | 75.78 | 76.74 | 76.90 |
| Reconciled Depreciation | - | 228.67 | 210.37 | 181.28 | 214.52 |
| Reconciled Cost Of Revenue | - | 8,129.12 | 1,335.55 | 1,399.73 | 1,472.73 |
| Total Unusual Items | - | -133.87 | -82.13 | -415.77 | -212.57 |
| Total Unusual Items Excluding Goodwill | - | -133.87 | -82.13 | -415.77 | -212.57 |
| Net Income Discontinuous Operations | - | 0 | -50.21 | -11.95 | -997.96 |
| Special Income Charges | - | -133.87 | -82.13 | -415.77 | -212.57 |
| Other Special Charges | 40.43 | - | -3.52 | 1.10 | - |
| Impairment Of Capital Assets | - | 0 | 0 | 307.11 | 0 |
| Restructuring And Mergern Acquisition | - | 133.87 | 82.13 | 108.65 | 212.57 |
| Other Operating Expenses | -6.19 | -5.25 | 6.93 | 13.32 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Accendra Health, Inc.this co. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Sanara MedTech Inc. | SMTI | $203M | -5.40 | 34.13 | -632.5% | 22.72 |
| TriSalus Life Sciences, Inc. | TLSI | $203M | -5.17 |
| - |
| - |
| - |
| - |
| - |
| -5.99 |
| 115.8% |
| -6.56 |
| Embecta Corp. | EMBC | $202M | 2.12 | -0.31 | -14.6% | 4.95 |
| Alector, Inc. | ALEC | $201M | - | 6.56 | -466.3% | - |
| Nkarta, Inc. | NKTX | $198M | - | 0.63 | -33.3% | - |
| Anika Therapeutics, Inc. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Peer Median | - | -5.28 | 0.89 | -24.0% | -2.48 | |